



11 April 2019

AIM: RENE

**ReNeuron Group plc**  
("ReNeuron" or the "Company")

**Share Purchases by Directors**

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 11 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by directors of the Company:

Name	Title	Number of Ordinary Shares purchased	Total beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
John Berriman	Non-executive Chairman	80,000	90,434	0.286
Simon Cartmell OBE	Non-executive Director	7,758	15,633	0.049
Professor Sir Chris Evans OBE	Non-executive Director	4,500	244,605	0.773
Dr Mike Owen	Non-executive Director	4,237	4,237	0.013

**ENDS**

**ENQUIRIES:**

**ReNeuron** +44 (0)20 3819 8400  
Olav Hellebø, Chief Executive Officer  
Michael Hunt, Chief Financial Officer

**Buchanan** +44 (0) 20 7466 5000  
Mark Court, Sophie Wills, Tilly Abraham

**Stifel Nicolaus Europe Limited** +44 (0) 20 7710 7600  
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

**Nplus1 Singer Advisory LLP** +44 (0) 20 7496 3000  
Aubrey Powell, Mark Taylor (Joint Broker)

**About ReNeuron**

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease,

retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit [www.reneuron.com](http://www.reneuron.com).

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	John Berriman	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Non-Executive Chairman	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	ReNeuron Group plc	
b)	LEI	2138003TU12CQ5TZ0137	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares 1p RENE – GB00BF5G6K95	
b)	Nature of the transaction	Purchase of ordinary shares	
c)	Price(s) and volume(s)	Price(s) 225p	Volume(s) 80,000
d)	Aggregated information	N/A	
e)	Date of the transaction	11 April 2019	
f)	Place of the transaction	London Stock Exchange AIM Market	

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Simon Cartmell OBE	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	ReNeuron Group plc	
b)	LEI	2138003TU12CQ5TZ0137	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares 1p RENE – GB00BF5G6K95	
b)	Nature of the transaction	Purchase of ordinary shares	
c)	Price(s) and volume(s)	Price(s) 225.5516p	Volume(s) 7,758

d)	Aggregated information	N/A
e)	Date of the transaction	<b>11 April 2019</b>
f)	Place of the transaction	London Stock Exchange AIM Market

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Professor Sir Chris Evans OBE	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	ReNeuron Group plc	
b)	LEI	<b>2138003TU12CQ5TZO137</b>	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares 1p RENE – GB00BF5G6K95	
b)	Nature of the transaction	Purchase of ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		221.5p	4,500
d)	Aggregated information	N/A	
e)	Date of the transaction	<b>11 April 2019</b>	
f)	Place of the transaction	London Stock Exchange AIM Market	

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Dr Mike Owen	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	ReNeuron Group plc	
b)	LEI	<b>2138003TU12CQ5TZO137</b>	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares 1p RENE – GB00BF5G6K95	
b)	Nature of the transaction	Purchase of ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		236p	4,237
d)	Aggregated information	N/A	
e)	Date of the transaction	<b>11 April 2019</b>	
f)	Place of the transaction	London Stock Exchange AIM Market	